Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

What Was Tested

The paper reports a study of Liraglutide, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Analyses were done on the full analysis set with missing values imputed by last observation carried forward; seven patients assigned to liraglutide did not receive treatment and thus did not meet criteria for inclusion in the full analysis set.

How the Study Was Run

In design terms this was a randomized, open-label and parallel-group study.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Liraglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The Liraglutide group and the comparison group ran side by side rather than switching.

The primary endpoint was change in HbA(1c) from baseline to week 26.

This trial is registered with ClinicalTrials.gov, number NCT00700817.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide 1, Hypoglycemic Agents, Liraglutide, Metformin and Pyrazines.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Liraglutide.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Lancet (London, England)), a journal based in England.

More context: the Liraglutide compound page.